The present invention concerns a process for the recovery and purification of glyoxylic acid from a process stream comprising glyoxylic acid and oxalic acid, wherein the process stream comprising glyoxylic acid and oxalic acid is subjected to a number of alternating separation and dehydration steps. The process comprising the steps of: (i) providing an aqueous solution comprising glyoxylic acid and oxalic acid; (ii) precipitating at least a portion of the oxalic acid using low-temperature crystallization at a temperature of at most 18? C.; (iii) separating the precipitated oxalic acid from the solution to obtain a solution depleted in oxalic acid; (iv) concentrating the solution depleted in oxalic obtained in step (iii) using reverse osmosis; and repeating steps (ii)-(iv) with the concentrated solution obtained in step (iv) until a purified glyoxylic acid stream with a predetermined degree of purity is obtained. The invention also relates to a system for carrying out the process.

The present invention concerns a process for the recovery and purification of glyoxylic acid from a process stream comprising glyoxylic acid and oxalic acid, wherein the process stream comprising glyoxylic acid and oxalic acid is subjected to a number of alternating separation and dehydration steps. The process comprising the steps of: (i) providing an aqueous solution comprising glyoxylic acid and oxalic acid; (ii) precipitating at least a portion of the oxalic acid using low-temperature crystallization at a temperature of at most 18? C.; (iii) separating the precipitated oxalic acid from the solution to obtain a solution depleted in oxalic acid; (iv) concentrating the solution depleted in oxalic obtained in step (iii) using reverse osmosis; and repeating steps (ii)-(iv) with the concentrated solution obtained in step (iv) until a purified glyoxylic acid stream with a predetermined degree of purity is obtained. The invention also relates to a system for carrying out the process.

Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.

Process and methods for making glycolic acid chemical intermediates and derivatives from biomass are described herein.

Process and methods for making glycolic acid chemical intermediates and derivatives from biomass are described herein.